Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 44,234

Document Document Title
WO/2018/013870A1
Provided herein are combinations of (a) ceftibuten or a pharmaceutically acceptable salt thereof, or a hydrate of the foregoing; and (b) clavulanic acid, or a pharmaceutically acceptable salt thereof for use in a method of treating or pr...  
WO/2018/007864A1
The invention relates to a medicament, the active principle of which is Salbutamol. It can be applied to the prevention and/or treatment of eye diseases or disorders, especially of Ametropia (myopia, Presbyopia), hereditary dystrophies o...  
WO/2018/009177A1
The invention contemplates a copolymer which is a graft or block copolymer useful to change the ocular surface temperature and other characteristics of biological or contact lens surfaces. Methods for use of these formulations and coatin...  
WO/2018/009385A1
Methods and compositions for treating ophthalmic disease, reducing retinal neovascularization and retinal vascular leakage using progenitor cells, such as postpartum-derived cells, and conditioned media from the cells, are disclosed.  
WO/2018/009562A1
Described herein are methods for treating a retinal degeneration in a subject, such as Leber's congenital amaurosis (LCA), retinitis pigmentosa (RP), and glaucoma. Also provided herein are methods of altering expression of one or more ge...  
WO/2018/003531A1
The present invention provides a pyrroloquinone quinone monosodium having a structure represented by formula (1).  
WO/2018/003908A1
According to the present invention wherein RPE cells are suspended in a medium that contains poloxamer and is pharmaceutically acceptable as an eye perfusion/washing liquid, the survival ratio of the RPE cells having been freeze-preserve...  
WO/2018/002873A1
The present invention relates to the use of 0-(3-piperidino-2-hydroxy-l-propyl)- nicotinic amidoxime (BGP15), its tautomers, enantiomers and pharmaceutically acceptable salts thereof the treatment of diseases characterised at least in pa...  
WO/2018/003867A1
The present invention provides a method for producing a compound represented by formula (I), which comprises a step for obtaining a compound represented by formula (I) by reacting a compound represented by formula (II) and an alkali meta...  
WO/2018/002105A1
The present invention relates to antisense oligonucleotides (oligomers) that are complementary to HTRA1, leading to modulation of the expression of HTRA1. Modulation of HTRA expression is beneficial for a range of medical disorders, such...  
WO/2018/003796A1
An ophthalmic product including: an ophthalmic composition which comprises (A) a water-soluble polymeric compound, (B) polyoxyethylene polyoxypropylene glycol, (C) at least one component selected from vitamin A, vitamin E, dibutylhydroxy...  
WO/2018/003961A1
The present invention relates to an emulsion-type eye drop preparation which contains 50,000 units/100 mL or more of vitamin A and at last one component selected from the group consisting of (A) 0.5% (w/v) or more of chondroitin sulfate ...  
WO/2018/005777A1
Pharmaceutical compositions comprising an active pharmaceutical ingredient, a high viscosity liquid carrier material, a hydrophobic solvent, and a hydrophilic solvent are disclosed. Also disclosed are methods of manufacturing and using t...  
WO/2017/222042A1
The application provides an ophthalmic pharmaceutical composition containing a compound of formula (I) or an ester, oxide, prodrug, or pharmaceutically acceptable salt or solvate thereof contained in a high-density lipoprotein. In formul...  
WO/2017/223498A1
The present disclosure provides compositions and methods for treating an auditory disease in a subject in need thereof comprising administering an effective amount of a gel-based precursor that includes an inner ear-specific therapeutic ...  
WO/2017/221008A1
The invention relates to compounds of general formula (I): wherein R1, R2, R3, R10 and X- are as defined herein. The compounds are inhibitors of the epithelial sodium channel (ENaC) and are useful for the treatment or prevention respirat...  
WO/2017/222083A1
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein n, X1, X2, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12and R13 are as defined in the specification, processes for their p...  
WO/2017/221128A1
The disclosure is directed to novel predictive methods and personalized therapies for treating dry eye disease (DED). Specifically, this disclosure relates to methods of treating a patient having DED by selectively administering a TNF╬▒ ...  
WO/2017/220544A1
The invention relates to a compound of formula (I) wherein R wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.  
WO/2017/220516A1
The invention relates to a compound of formula (I) containing at least one diazirenyl. The compound of formula (I) is a type-2 cannabinoid (CB2) receptor modulator and can be used as a medicament.  
WO/2017/219080A1
Provided herein are methods for treating or preventing myopia, or for inhibiting the development of myopia, comprising administering to a subject in need thereof an effective amount of an agent capable of increasing nitric oxide levels i...  
WO/2017/221011A1
A treatment of ocular disease, and more specifically disorders of the cornea, using the polypeptide FKBP-L and peptide fragments thereof is provided.  
WO/2017/215524A1
Provided are an anti-human IL-17A monoclonal antibody, and a preparation method and a use thereof. The anti-human IL-17A monoclonal antibody can specifically bind to human IL-17A and has a good effect for inhibiting the secretion of infl...  
WO/2017/217478A1
Provided is a combination agent which is composed of a halogenated isoquinoline derivative and another active ingredient and has an excellent ocular hypotensive effect. An ophthalmic composition comprising the components (A) and (B) ment...  
WO/2017/217450A1
The purpose of the present invention is to provide an ophthalmic pharmaceutical product which, while an ophthalmic solution containing brimonidine and/or a salt thereof, brinzolamide and/or a salt thereof, a carboxyvinyl polymer, and a d...  
WO/2017/218942A1
The present disclosure relates to a composition including non-autologous plasma or serum and a polymer; method of treating ophthalmic diseases (e.g., dry eye syndrome) or moisturizing and/or repairing non-keratinized surfaces including n...  
WO/2017/217477A1
Provided is a technology whereby a decrease in the contained amount of a halogenated isoquinoline derivative is inhibited in an aqueous composition containing the halogenated isoquinoline derivative and timolol. The aqueous composition c...  
WO/2017/211246A1
The present invention relates to a substituted fused imidazole cyclic compound and a composition containing said compound and application thereof. Specifically disclosed is the fused imidazole cyclic compound represented by formula (I), ...  
WO/2017/212422A1
Methods and topically administrable compositions for treating or preventing viral infections or allergic conditions or the symptoms thereof in a mammalian subject in need thereof which comprises topically administering to the subject a c...  
WO/2017/211248A1
Disclosed are a substituted imidazoquinazoline compound as represented by formula (I), and a pharmaceutical composition containing its crystalline form, pharmaceutically acceptable salt, prodrug, stereoisomer, isotopic variant, hydrate, ...  
WO/2017/207985A1
The invention provides new polymorphs of N-[(2,6-difluoro-3-methoxyphenyl)methyl]-3- (methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}meth yl)pyrazole-4-carboxamide, pharmaceutical compositions containing them and their use in the...  
WO/2017/207124A1
Dihomo-gamma-linolenic acid (DGLA) or a composition comprising DGLA for use in the prophylaxis of allergic disease in the offspring of mammalian subject wherein said DGLA is administered to said subject pre-pregnancy and/or during pregna...  
WO/2017/207983A1
The present invention provides a selection of compounds of formula (I): (I) compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasm...  
WO/2017/208170A1
The present invention relates to a process for the preparation of an extract from branches of Sambucus nigra L, the so-obtained extract and the use thereof in a series of dermocosmetic products.  
WO/2017/208172A1
The present invention relates to a composition for use as a medicament, in the form of a gel with characteristics of a reversible thermogel, based on one or more poloxamers, water and optionally excipients, and an effective amount of an ...  
WO/2017/208129A1
The present invention relates to a pharmaceutical composition comprising the oxy radical of 2-cyano-1-(1-hydroxy-2,2,5,5-tetramethylpyrrolidin-3-yl)-3-( pyridin-3-yl) guanidine, or an enantiomer, diastereomer, racemate, or a pharmaceutic...  
WO/2017/209721A1
The invention is related to a drug that is derived from various enzymes present in the human saliva and that is embodied to prevent formation of corneal clouding and cataract diseases. The drug that is embodied to achieve the objects of ...  
WO/2017/209226A1
[Problem] To provide an agent for preventing, through an increase in the amount of reduced glutathione within the lens, cataract that progresses due to oxidative stress induced by ultraviolet irradiation or aging, diabetes, and prolonged...  
WO/2017/204298A1
This invention relates to a method for treatment of persistent edema in patients with exudative age-related macular degeneration. In particular, the present invention relates to treatment of wet age-related macular degeneration with intr...  
WO/2017/203550A1
The present invention relates to a liquid preparation for soft contact lenses, more particularly hydrogel contact lenses or silicone hydrogel contact lenses. The liquid preparation according to the present invention for contact lenses co...  
WO/2017/202896A1
The invention provides novel compounds having the general formula (I) wherein R1, R1', R2, R3, R4 are as defined herein, compositions including the compounds and methods of using the compounds.  
WO/2017/202957A1
The present invention pertains to antagonists and inhibitors of soluble epoxide hydrolase (sEH) and 19,20-dihydroxydocosapentaenoic acid (19,20-DHDP) for use as a therapeutic in the treatment of eye disorders that are characterized by pe...  
WO/2017/201255A1
A lacrimal drug delivery device includes a reservoir configured to hold a drug. The reservoir is moveable between a relaxed state and an expanded state. A connector is fluidly coupled to the reservoir and a lumen is formed in the connect...  
WO/2017/198753A1
The present invention relates to compounds for use in the prevention and/or treatment of PAR-related diseases, such as for example: pain and ocular disorders. More in particular, the present invention provides bis(acetamidophenyl) guanid...  
WO/2017/197791A1
A Radix Polygoni Multiflori and Fructus Lycii liquor, consisting of the components of: 150 g of Radix Polygoni Multiflori, 80 g of Radix Rehmanniae Preparata, 100 g of Fructus Lycii, 30g Rhizoma Polygonati, 30 g of Radix Angelicae Sinens...  
WO/2017/197787A1
A wolfberry blood-enriching liquor, the ingredient composition thereof being: 8g of fructus lycii, 8g of angelica sinensis, 8g of ligusticum chuanxiong, 8g of radix paeoniae alba, 8g of radix rehmanniae preparata, 10g of panax ginseng, 5...  
WO/2017/201433A1
The disclosure provides methods of preventing or treating mitochondrial myopathy in a mammalian subject, reducing risk factors associated with mitochondrial myopathy, and/or reducing the likelihood or severity of mitochondrial myopathy. ...  
WO/2017/196881A1
The present disclosure provides a combination of a fused bicyclic amine compound and an anti-inflammatory agent for treating ocular inflammatory disorders and diseases. Further provided are pharmaceutical compositions of the compound and...  
WO/2017/192928A1
A treatment for ocular rosacea using p38 and Erk kinase pathway inhibitors, which are believed to block the initial reaction to rosacea triggers and thus make it possible to prevent or minimize the skin reaction. The treatment is premise...  
WO/2017/190568A1
Disclosed are an amine solvate of a sodium-glucose linked transporter (SGLT) inhibitor, and a preparation method and application thereof. The SGLT inhibitor is (1S,2S,3S,4R,5S)-5-(3-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl) methyl)-4-ethylb...  

Matches 1 - 50 out of 44,234